한국형 우울장애 약물치료 알고리듬 2021 (II): 임상 아형
Korean Medication Algorithm Project for Depressive Disorder 2021 (II): The Subtypes of Depression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) was developed in 2002 and revised in 2006, 2012, 2017. In 2021, the fifth edition was published. This edition reflected new findings and the latest trends in the areas of pharmacological treatment. The aim of this study is to present strategies and treatment options according to the subtype of depression using data from the KMAP-DD-2021. Methods Ninety-seven psychiatrists with clinical experience in depressive disorder were selected. The questionnaires for KMAP-DD 2021 were sent to participants via mail. KMAP-DD 2021 consists of overall treatment strategies and treatment options under specific circumstances. Each treatment strategy or treatment option was evaluated with an overall score of nine and was divided into the three phases of recommendation that include primary, secondary, and tertiary. Results For persisting depressive disorder, antidepressant monotherapy including selectiveserotonin reuptake inhibitor (SSRI) (escitalopram, fluoxetine, sertraline, paroxetine), serotoninnorepinephrine reuptake inhibitor (SNRI) (desvenlafaxine, venlafaxine, duloxetine, milnacipran), vortioxetine, and mirtazapine, was recommended as first-line medications. For melancholia of major depressive disorder, SSRI, SNRI, vortioxetine, and mirtazapine also were recommended as first-line medications. For mixed features, SSRI, bupropion, mirtazapine, SNRI, except for duloxetine, and milnacipran were recommended as first-line medications. For anxious distress, SSRI, mirtazapine, and SNRI, except milnacipran, were recommended as first-line medications. Conclusion The preferences of antidepressants by experts differed according to the subtype of depression. These findings suggest that experts treat patients with a major depressive disorder after considering the subtype of depression involved.
Abstract
Objectives The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) was developed in 2002 and revised in 2006, 2012, 2017. In 2021, the fifth edition was published. This edition reflected new findings and the latest trends in the areas of pharmacological treatment. The aim of this study is to present strategies and treatment options according to the subtype of depression using data from the KMAP-DD-2021. Methods Ninety-seven psychiatrists with clinical experience in depressive disorder were selected. The questionnaires for KMAP-DD 2021 were sent to participants via mail. KMAP-DD 2021 consists of overall treatment strategies and treatment options under specific circumstances. Each treatment strategy or treatment option was evaluated with an overall score of nine and was divided into the three phases of recommendation that include primary, secondary, and tertiary. Results For persisting depressive disorder, antidepressant monotherapy including selectiveserotonin reuptake inhibitor (SSRI) (escitalopram, fluoxetine, sertraline, paroxetine), serotoninnorepinephrine reuptake inhibitor (SNRI) (desvenlafaxine, venlafaxine, duloxetine, milnacipran), vortioxetine, and mirtazapine, was recommended as first-line medications. For melancholia of major depressive disorder, SSRI, SNRI, vortioxetine, and mirtazapine also were recommended as first-line medications. For mixed features, SSRI, bupropion, mirtazapine, SNRI, except for duloxetine, and milnacipran were recommended as first-line medications. For anxious distress, SSRI, mirtazapine, and SNRI, except milnacipran, were recommended as first-line medications. Conclusion The preferences of antidepressants by experts differed according to the subtype of depression. These findings suggest that experts treat patients with a major depressive disorder after considering the subtype of depression involved.
참고문헌 (17)
- S. Nassir Ghaemi, "Bipolar Spectrum: A Review of the Concept and a Vision for the Future", PSYCHIATRY INVESTIGATION, 10(3), pp.218~224 (2013), 대한신경정신의학회[DOI]
- Seon-Cheol Park, "Diagnostic Issues of Depressive Disorders from Kraepelinian Dualism to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition", PSYCHIATRY INVESTIGATION, 16(9), pp.636~644 (2019), 대한신경정신의학회[DOI]
- Uher R, "Major depressive disorder in DSM-5 : implications for clinical practice and research of changes from DSM-IV", Depress Anxiety, 31, pp.459~471 (2014)
- Park SC, "Challenges and strategies for current classifications of depressive disorders : proposal for future diagnostic standards", Adv Exp Med Biol, 1305, pp.103~116 (2021)
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- American Psychiatric Association, "The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia" (2021)
- Malhi GS, "The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders : major depression summary", Bipolar Disord, 22, pp.788~804 (2020)
- Ni YG, "Blockage of 5HT2C serotonin receptors by fluoxetine(Prozac)", Proc Natl Acad Sci U S A, 94, pp.2036~2040 (1997)
- Schmitt JA, "Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man", J Psychopharmacol, 16, pp.207~214 (2002)
- Norman TR, "Agomelatine for depression : expanding the horizons", Expert Opin Pharmacother, 20, pp.647~656 (2019)
- Sohn CH, "Treatment of seasonal affective disorder : unipolar versus bipolar differences", Curr Psychiatry Rep, 6, pp.478~485 (2004)
- Galima SV, "Seasonal affective disorder : common questions and answers", Am Fam Physician, 102, pp.668~672 (2020)
- McIntyre RS, "Implementing treatment strategies for different types of depression", J Clin Psychiatry, 77(Suppl 1), pp.9~15 (2016)
- Young-Min Park, "The Mixed-Features Specifier of Major Depressive Disorder in DSM-5: Is It Practical?", PSYCHIATRY INVESTIGATION, 15(11), pp.1009~1010 (2018), 대한신경정신의학회[DOI]
- Koukopoulos A, "Mixed features of depression : why DSM-5 is wrong(and so was DSM-IV)", Br J Psychiatry, 203, pp.3~5 (2013)
- Sani G, "Koukopoulos’ diagnostic criteria for mixed depression : a validation study", J Affect Disord, 164, pp.14~18 (2014)
- Ghaemi SN, "DSM-5 and the miracle that never happens", Acta Psychiatr Scand, 129, pp.410~412 (2014)